What is Juno Diagnostics?
Juno Diagnostics is at the forefront of developing advanced genetic testing solutions designed to democratize access to critical health insights. Their flagship product is a non-invasive prenatal testing (NIPT) solution engineered for enhanced accessibility and superior genetic testing results. This innovative approach simplifies the sample collection process and bypasses the high costs, extended waiting periods, and the need for traditional phlebotomy associated with conventional NIPT methods. Headquartered in San Diego, California, Juno Diagnostics is strategically positioned to address a significant need in the healthcare market for more efficient and cost-effective genetic diagnostics.
How much funding has Juno Diagnostics raised?
Juno Diagnostics has raised a total of $25M across 1 funding round:
Series A
$25M
Series A (2021): $25M with participation from Perceptive Advisors
Key Investors in Juno Diagnostics
Perceptive Advisors
Perceptive Advisors is an investment firm that likely focuses on the healthcare and biotechnology sectors, given their participation in a company developing genetic testing solutions.
What's next for Juno Diagnostics?
With the infusion of $25M in a major strategic investment, Juno Diagnostics is poised for accelerated expansion and product development. This enterprise-level funding is expected to fuel advancements in their genetic testing technology, potentially broadening their NIPT solution's reach and impact. The company's focus on simplifying sample collection and improving access to high-quality genetic information suggests a strategic direction towards greater market penetration and the establishment of new healthcare partnerships. Juno Diagnostics' commitment to innovation in prenatal diagnostics positions them as a key player in the evolving landscape of personalized medicine.
See full Juno Diagnostics company page
